<code id='AFC06DE560'></code><style id='AFC06DE560'></style>
    • <acronym id='AFC06DE560'></acronym>
      <center id='AFC06DE560'><center id='AFC06DE560'><tfoot id='AFC06DE560'></tfoot></center><abbr id='AFC06DE560'><dir id='AFC06DE560'><tfoot id='AFC06DE560'></tfoot><noframes id='AFC06DE560'>

    • <optgroup id='AFC06DE560'><strike id='AFC06DE560'><sup id='AFC06DE560'></sup></strike><code id='AFC06DE560'></code></optgroup>
        1. <b id='AFC06DE560'><label id='AFC06DE560'><select id='AFC06DE560'><dt id='AFC06DE560'><span id='AFC06DE560'></span></dt></select></label></b><u id='AFC06DE560'></u>
          <i id='AFC06DE560'><strike id='AFC06DE560'><tt id='AFC06DE560'><pre id='AFC06DE560'></pre></tt></strike></i>

          
          WSS
          Traffic on the Longfellow Bridge and the Kendall Square skyline are seen. -- health coverage from STAT
          Michael Dwyer/AP

          Around this time three years ago, while most of us navigated pandemic life, real estate developers across Greater Boston looked to life-science laboratories, and saw dollar signs.

          The white-collar office workers who’d long filled downtown towers were largely staying home (unless they worked in commercial real estate). The future of cities had rarely been murkier.

          advertisement

          But many biotech companies, like Cambridge’s Moderna, were busier than ever, and growing fast. Life-science companies, and the lab buildings that house them, looked like a sure bet for investors. Money poured in to drug companies by the billions — from venture capitalists, the stock market, the National Institutes of Health. And big real estate investors followed, launching a wave of speculative lab development all over Greater Boston.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment